Optimµm® can create fine microcapsules with high drug loading surrounded by a drug-free shell to provide delayed release for pH-sensitive applications. Existing methods for enteric formulations often require multiple coating steps to ensure reproducible particle performance. Often, the approaches yield very large granules or beads that require placement within a capsule because they are too large to be palatable.
Precise control of particle size and composition enable precise active pharmaceutical ingredient (API) release rates, including delayed release (DR). Unlike other encapsulation techniques, Optimμm technology’s precise control over microcapsule properties seals the drug inside small, palatable microcapsules that can then release drug after passing through stomach acid to create a cost-effective platform for microencapsulating pH-sensitive APIs.
The Optimµm microencapsulation technology offers significant advantages for pediatric and geriatric drug reformulations. The simple, robust, and precise particle engineering allows for an unprecedented amount of control over the final product, which would improve dosing efficiency and efficacy and reduce adverse effects. This highly-flexible and customizable encapsulation platform provides a convenient means of masking the bitter flavor of many drugs while also establishing a delivery system that is adaptable to many patient-friendly formats. The ability to transport and store these particles in dry powder form also makes this a convenient solution for personalized dosing and patient-specific treatment strategies. This platform addresses numerous pediatric medicine issues, and the technology provides for patient-specific, accurate, and palatable dosing.